Fri. Oct 15th, 2021
AstraZeneca Covid seeks emergency U.S. approval for antibody treatment.

AstraZeneca has requested urgent approval from the U.S. Food and Drug Administration for long-acting antibody combination therapies to prevent Kovid-19.

AstraZeneca said in a statement on Tuesday that the UK drug manufacturer’s experiments had reduced the risk of contracting Kovid-19 by 77 percent after using the treatmentIf authorized, it will be the first therapy to prevent the coronavirus from spreading.

Maine Pangallos, executive vice president, said: “People at risk, such as those with a low level of immunosuppression, will not be able to get a protective response after being vaccinated, and the risk of contracting Kovid-19 remains high.”

“With this first global regulatory filing, we are one step closer to providing an additional alternative to vaccinating against Kovid-19,” he said.

Global Version Samsung Galaxy M51 M515F-DSN Mobile Phone 128GB ROM 8GB RAM 6.7″ 7000mAh NFC Snapdragon 730G Smartphone

By admin

One thought on “AstraZeneca Covid seeks emergency U.S. approval for antibody treatment.”
  1. Amazing blog! Is your theme custom made or did you download it from somewhere? A theme like yours with a few simple adjustements would really make my blog stand out. Please let me know where you got your theme. Thank you

Leave a Reply

Your email address will not be published. Required fields are marked *